People · Operator
Named in public records as an officer, director or promoter · active 2009–2017 · Other Technology, Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Acquia Inc | — | Other Technology | Series C | $166.5M | $1.7B | 2012 |
| QuorumLabs, Inc. | — | Other Technology | Series A | $36.1M | $126.8M | 2013 |
| Zephyr Health, Inc. | — | Other Health Care | Series B | $17.5M | $387.2M | 2015 |
| Mimosa Systems Inc | — | Other Technology | Series A | $10.6M | $50.4M | 2009 |
| Anelixis Therapeutics, Inc. | — | Biotechnology | Series A | $7.9M | $36.2M | 2017 |
Paul Sallaberry at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Sallaberry on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joseph Horowitz | 2 | 7 |
| Brook Byers | 1 | 13 |
| Sumant Mandal | 1 | 13 |
| Michael Skok | 1 | 12 |
| Navin Chaddha | 1 | 12 |
| Vivek Mehra | 1 | 8 |
| Thomas Erickson | 1 | 7 |
| Jose Suarez | 1 | 7 |
| John Mandile | 1 | 7 |
| Brian Paul | 1 | 6 |
| Michael J. Sheridan | 1 | 3 |
| Tom Bogan | 1 | 3 |
| James Heywood | 1 | 3 |
| T. M. Ravi | 1 | 3 |
| Walter Ogier | 1 | 3 |
| Martin J. Bradford | 1 | 2 |
| Andrew D. Swart | 1 | 2 |
| William E. Kehret | 1 | 2 |
| Laurent Asscher | 1 | 2 |
| Jerome C. Nathan | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.